Insights in Endocervical Mucus Secretion

Conditions

• Cervical Mucus

Eligibility Criteria

Sex

FEMALE

Age

21 Years - 40 Years

Healthy Volunteers

Accepted

Interventions

• Gonadotropin Releasing Hormone Antagonists Relugolix — DRUG
  Gonadotropin releasing hormone antagonist (gnRH) taken for 10 days starting during the midluteal phase.

Study Details

Single arm interventional study looking at biological outcomes at 4 time points throughout the cycle before and after taking an oral gonadotropin-releasing hormone antagonist (gnRH). Samples of whole blood, endocervical mucus, endocervical biopsy, and vaginal swab will be collected.

Key Dates

Start date

Jan 2, 2026

Status verified

Jan 2026

Primary completion

Aug 31, 2027

Completion

Aug 31, 2027

Study Design

Enrollment

15 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Arms

• Experimental: Relugolix
  Participants will take Reugolix for 10 days starting at the midluteal time point (6-9 days after "high fertility" based on ovulation test)

Primary Outcome Measure

Cervical mucus scores [ Time Frame: Cervical mucus will be collected and compared across 4 time points during the menstrual cycle (follicular [3-5 days following start of menses], ovulatory, luteal, ovarian suppression [9-11 days following Relugolix initiation]) ]

Central Contacts

• Women's Health Research Unit Recruitment Line
  503-494-3666
  [email protected]

Locations (1)

Find similar trials in Portland, OR